News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,235 Results
Type
Article (42189)
Company Profile (436)
Press Release (669610)
Section
Business (208685)
Career Advice (2021)
Deals (36001)
Drug Delivery (103)
Drug Development (83546)
Employer Resources (173)
FDA (16409)
Job Trends (15085)
News (352675)
Policy (33048)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2636)
Accelerated approval (5)
Adcomms (24)
Allergies (82)
Alliances (50902)
ALS (88)
Alzheimer's disease (1409)
Antibody-drug conjugate (ADC) (124)
Approvals (16396)
Artificial intelligence (249)
Autoimmune disease (19)
Automation (14)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (102)
Biotechnology (330)
Bladder cancer (63)
Brain cancer (25)
Breast cancer (260)
Cancer (2074)
Cardiovascular disease (173)
Career advice (1687)
Career pathing (29)
CAR-T (147)
Cell therapy (420)
Cervical cancer (19)
Clinical research (67539)
Collaboration (812)
Compensation (473)
Complete response letters (24)
COVID-19 (2641)
CRISPR (40)
C-suite (223)
Cystic fibrosis (103)
Data (2017)
Decentralized trials (2)
Denatured (26)
Depression (46)
Diabetes (254)
Diagnostics (6397)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (119)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (92)
Earnings (87462)
Editorial (36)
Employer branding (21)
Employer resources (147)
Events (115267)
Executive appointments (666)
FDA (17552)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (726)
Gene editing (105)
Generative AI (19)
Gene therapy (305)
GLP-1 (724)
Government (4471)
Grass and pollen (4)
Guidances (49)
Healthcare (19142)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (27)
Infectious disease (2776)
Inflammatory bowel disease (139)
Inflation Reduction Act (11)
Influenza (49)
Intellectual property (88)
Interviews (311)
IPO (16768)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (34)
Layoffs (484)
Leadership (17)
Legal (7978)
Liver cancer (71)
Lung cancer (300)
Lymphoma (136)
Machine learning (4)
Management (58)
Manufacturing (277)
MASH (64)
Medical device (13477)
Medtech (13482)
Mergers & acquisitions (19710)
Metabolic disorders (667)
Multiple sclerosis (74)
NASH (19)
Neurodegenerative disease (93)
Neuropsychiatric disorders (30)
Neuroscience (1930)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2488)
Now hiring (37)
Obesity (362)
Opinion (220)
Ovarian cancer (74)
Pain (82)
Pancreatic cancer (77)
Parkinson's disease (144)
Partnered (20)
Patents (207)
Patient recruitment (98)
Peanut (47)
People (58489)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21216)
Phase II (29801)
Phase III (22046)
Pipeline (1082)
Podcasts (74)
Policy (122)
Postmarket research (2601)
Preclinical (9052)
Press Release (67)
Prostate cancer (97)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (383)
Real estate (6009)
Recruiting (66)
Regulatory (22620)
Reports (46)
Research institute (2414)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (39)
Schizophrenia (72)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (56)
Southern California (2158)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3757)
State (2)
Stomach cancer (14)
Supply chain (61)
Tariffs (11)
The Weekly (46)
United States (21913)
Vaccines (676)
Venture capitalists (38)
Webinars (13)
Weight loss (244)
Women's health (35)
Worklife (16)
Date
Today (58)
Last 7 days (674)
Last 30 days (2655)
Last 365 days (34419)
2025 (8518)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (54)
Alaska (7)
Arizona (232)
Arkansas (14)
Asia (39125)
Australia (6515)
California (5717)
Canada (1892)
China (487)
Colorado (254)
Connecticut (268)
Delaware (131)
Europe (85432)
Florida (832)
Georgia (196)
Idaho (57)
Illinois (518)
India (24)
Indiana (296)
Iowa (10)
Japan (145)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (61)
Maryland (855)
Massachusetts (4372)
Michigan (211)
Minnesota (377)
Mississippi (2)
Missouri (78)
Montana (29)
Nebraska (25)
Nevada (56)
New Hampshire (66)
New Jersey (1626)
New Mexico (30)
New York (1626)
North Carolina (989)
North Dakota (7)
Northern California (2488)
Ohio (195)
Oklahoma (14)
Oregon (37)
Pennsylvania (1279)
Puerto Rico (9)
Rhode Island (28)
South America (1108)
South Carolina (18)
South Dakota (1)
Southern California (2158)
Tennessee (95)
Texas (852)
Utah (167)
Virginia (134)
Washington D.C. (59)
Washington State (536)
West Virginia (3)
Wisconsin (50)
712,235 Results for "regulus therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Regulus Therapeutics Inc. “Regulus”), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024, at 1:00 p.m. ET.
April 30, 2024
·
3 min read
Business
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
8 min read
Biotech Beach
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Inc. today announced the promotion of Rekha Garg , M.D., M.S., to Chief Medical Officer effective May 16, 2024.
May 16, 2024
·
4 min read
Biotech Beach
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Regulus Therapeutics Inc. announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.
June 4, 2024
·
5 min read
Biotech Beach
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Inc. announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors.
March 12, 2024
·
4 min read
Business
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
March 21, 2024
·
10 min read
BioMidwest
Bio-Techne Highlights Recently Announced Top-line Biomarker Data From Partner, Regulus Therapeutics, Using the Company’s Proprietary Technology
Bio-Techne Corporation and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced continued technical and clinical collaboration following release of Regulus’ positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease.
May 22, 2024
·
3 min read
Drug Development
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
June 24, 2024
·
8 min read
Business
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.
November 9, 2023
·
9 min read
Drug Development
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Inc. today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months.
May 6, 2024
·
5 min read
1 of 71,224
Next